PubMed İndeksli Yayınlar Koleksiyonu

Permanent URI for this collectionhttps://hdl.handle.net/20.500.12514/3597

Browse

Now showing 1 - 2 of 2

Determination of Body Image and Self-Efficacy Levels in Patients After Cornea Transplantation
(Elsevier Espana Slu, 2024) Genc, H.; Tanriverdi, Seher; Sen, M. A.
Purpose: The study aimed to determine body image and levels after surgery in cornea transplant patients. Materials and methods: The population of this cross-sectional study was composed of 383 patients presented to the Eye Bank unit of a University Hospital after corneal transplantation. Sample size of 193 patients was calculated with 0.5 power, a margin of error of 5%, representing 95% of the universe. The data were collected through face-to-face interviews with the patients by the researcher and the study was completed with 178 patients in September - November 2022. The data were collected using a Patient Information Form, the Body Image Scale, and the General Self-Efficacy Scale. Parametric tests, Pearson Correlation, Student's T -test, and One-Way Analysis of Variance tests were performed were used in the data analysis. Results: It was determined that the mean Body Image Scale score of the transplant patients participating in the study was 159.41 +/- 36.99 and the mean Self-Efficacy Scale score was 30.37 +/- 8.31. When the comparison of the mean scores was examined, the difference between the mean scores of gender, marital status, occupation, and body image scale was statistically significant (P < .05), while the difference between the self-efficacy mean scores was not statistically significant (P > .05). There was a positive, moderately strong significant relationship between body image and the self-efficacy of the patients (P < .01) (r = .57) Conclusion: It was found that the patient's body image and self-efficacy levels were high, and self-efficacy increased as the body image increased. (c) 2023 Elsevier Espana, S.L.U. All rights reserved.
Liraglutide and Empagliflozin Alleviate Diabetic Cardiomyopathy by Reducing Oxidative Stress and Inflammation
(Academia Nacional de Medicina, 2025) Uçar-Ekin, C.; Oflazoğllu-Diken, H.; Baksi, N.; Aşır, F.; Şahika-Gökdemir, G.
Background: Diabetes mellitus (DM) is a growing metabolic disease worldwide, associated with severe complications. Glucagon-like peptide-1 analogs and sodium-glucose cotransporter-2 inhibitors are promising therapeutic options for diabetic cardiomyopathy (DCM), although their cardioprotective mechanisms are not yet fully understood. Objective: This study evaluates the effects of liraglutide and empagliflozin on oxidative stress, inflammation, and histological changes in cardiac tissue in DCM. Materials and methods: Thirty-seven male Wistar albino rats were divided into four groups. Diabetes was induced in three groups using streptozotocin and nicotinamide. The groups were: (1) Control, (2) DM, (3) DM + Liraglutide (0.6 mg/kg, subcutaneously, 8 weeks), and (4) DM + Empagliflozin (30 mg/kg, oral gavage, 8 weeks). Blood samples were analyzed through enzyme-linked immunosorbent assay for tumor necrosis factor-α (TNF-α), interleukin-1 (IL-1), malondialdehyde (MDA), superoxide dismutase (SOD), advanced glycation end (AGE) products, and insulin. Cardiac tissue was examined histopathologically. Results: Diabetes significantly increased blood glucose, IL-1, TNF-a, MDA, and AGE (p < 0.01), while SOD levels decreased (p < 0.01), alongside myocardial damage. Liraglutide and empagliflozin improved all parameters (p < 0.01). Conclusion: Liraglutide and empagliflozin mitigate diabetes-induced cardiac damage, likely by reducing fibrosis, oxidative stress, and inflammation. © 2025 Academia Nacional de Medicina de México, A.C. Publicado por Permanyer.

Browse

Browsing PubMed İndeksli Yayınlar Koleksiyonu by Language "es"